CounterX Therapeutics to Present at the 88th Annual College on Problems of Drug Dependence (CPDD) Scientific Meeting
PRESS RELEASE CounterX Therapeutics to Present at the 88th Annual College on Problems of Drug Dependence (CPDD) Scientific Meeting Company leadership to highlight advances in the developm ...
CounterX Therapeutics Invited to Present at Science2Startup
PRESS RELEASE CounterX Therapeutics Invited to Present at Science2Startup SEATTLE, WA – (April 29, 2026) CounterX Therapeutics today announced that the company has been selected to presen ...
CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose
PRESS RELEASE CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose SEATTLE ...
CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders
PRESS RELEASE CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders SEATTLE, WA – (February 26, 2026) CounterX Therapeutic ...
CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model
PRESS RELEASE CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model SEA ...